Abstract
Hypertension is the major modifiable risk factor for fatal, nonfatal strokes and other vascular diseases. In a pooled analysis of 61 prospective studies including about one million individuals, the reported risk of stroke increased progressively with blood pressure from values as low as 115/75 mm/Hg. Each increment of 20/10 mm/Hg doubles the risk of cardiovascular disease and such a correlation is consistent at all ages. Blood pressure lowering strongly reduces the risk of either first stroke or recurrent stroke but the possibility that specific drugs may prevail over others for protection from stroke remains unclear. There is some evidence that specific classes of antihypertensive drugs have different effects and/or their pharmacological actions differ in patient subgroups. Currently, there are five classes of first-line blood pressure lowering drugs: diuretics, beta-blockers, calcium channel blockers, angiotensin-converting inhibitors and angiotensin II receptor blockers. This review evaluates the development of antihypertensive therapies and the latest studies of arterial hypertension and stroke prevention.
Keywords: Stroke prevention, risk factors, hypertension
Current Hypertension Reviews
Title: Are there Differences in Stroke Prevention with Different Blood Pressure Lowering Agents?
Volume: 5 Issue: 2
Author(s): Maurizio Paciaroni and Julien Bogousslavsky
Affiliation:
Keywords: Stroke prevention, risk factors, hypertension
Abstract: Hypertension is the major modifiable risk factor for fatal, nonfatal strokes and other vascular diseases. In a pooled analysis of 61 prospective studies including about one million individuals, the reported risk of stroke increased progressively with blood pressure from values as low as 115/75 mm/Hg. Each increment of 20/10 mm/Hg doubles the risk of cardiovascular disease and such a correlation is consistent at all ages. Blood pressure lowering strongly reduces the risk of either first stroke or recurrent stroke but the possibility that specific drugs may prevail over others for protection from stroke remains unclear. There is some evidence that specific classes of antihypertensive drugs have different effects and/or their pharmacological actions differ in patient subgroups. Currently, there are five classes of first-line blood pressure lowering drugs: diuretics, beta-blockers, calcium channel blockers, angiotensin-converting inhibitors and angiotensin II receptor blockers. This review evaluates the development of antihypertensive therapies and the latest studies of arterial hypertension and stroke prevention.
Export Options
About this article
Cite this article as:
Paciaroni Maurizio and Bogousslavsky Julien, Are there Differences in Stroke Prevention with Different Blood Pressure Lowering Agents?, Current Hypertension Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157340209788166887
DOI https://dx.doi.org/10.2174/157340209788166887 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization
Current Topics in Medicinal Chemistry Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways
Current Drug Targets Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Treatment of Mild Cognitive Impairment (MCI)
Current Alzheimer Research Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology Structure and Thermodynamics of Drug-RNA Aptamer Interactions
Mini-Reviews in Medicinal Chemistry Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Systems Biology Approaches to a Rational Drug Discovery Paradigm
Current Topics in Medicinal Chemistry